Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (17 April 2018)

The US Patent Office issues new patents every Tuesday. Australian assignees generally get two or three healthcare and biotech-related patents a week while New Zealand assignees get one every three or four weeks.

Australian grants

Here are the 47 patents relevant to Australia's Life Sciences sector that have been granted in 2018, for an issuance rate of 2.9 per week:

US Patent 9,944,701, Methods of treating cancer with antibodies that bind P2X7 receptors, Biosceptre International Ltd, 17 April 2018
US Patent 9,943,597, Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder, Immuron, 17 April 2018
US Patent 9,943,584, Non-typeable haemophilus influenzae vaccines and their uses, Hunter Immunology Ltd, 17 April 2018
US Patent 9,943,573, Treatment of ocular neovascularization using anti-VEGF proteins, Avalanche Australia Pty Ltd, 17 April 2018
US Patent 9,943,564, Anti-pathogenic methods, Hexima, 17 April 2018
US Patent 9,943,500, Methods of treating topical microbial infections, Luoda Pharma Pty Ltd, 17 April 2018
US Patent 9,932,330, Piperazine derivatives for treating disorders, University of Nottingham and University of New South Wales, 3 April 2018
US Patent 9,931,391, Prevention and treatment of Mycobacterium infection, University of Sydney and Centenary Institute of Cancer Medicine and Cell Biology, 3 April 2018
US Patent 9,931,289, Cosmetic or pharmaceutical formulation, Forward Scout Enterprises Pty Ltd, 3 April 2018
US Patent 9,925,236, Reconstituted HDL formulation, CSL Ltd, 27 March 2018
US Patent 9,925,163, Methods of treating neurodevelopmental diseases and disorders, Deakin University and Florey Institute of Neuroscience and Mental Health, 27 March 2018
US Patent 9,920,009, UV absorbing compounds, compositions comprising same and uses thereof, Coral Sunscreens Pty Ltd, 20 March 2018
US Patent 9,919,015, Composition and method for inhibiting herpesviridae infections, Viratec Pty Ltd, 20 March 2018
US Patent 9,913,858, Prevention and treatment of toxicosis, Meat and Livestock Australia and Charles Sturt University, 13 March 2018
US Patent 9,907,778, Anticancer agent comprising aminoacetonitrile compound as active ingredient, PharmAust, 6 March 2018
US Patent 9,901,632, Human herpesvirus immunotherapy, QIMR Berghofer Medical Research Institute, February 27, 2018
US Patent 9,896,499, Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis, Opthea, 20 February 2018
US Patent 9,896,443, Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof, Peter MacCallum Cancer Institute, 20 February 2018
US Patent 9,895,414, Inhibition of cancer growth and metastasis, Royal Melbourne Institute of Technology and Abregen Pty Ltd, 20 February 2018
US Patent 9,895,407, Disinfecting formulations and uses thereof, Sunny Wipes Pty Ltd, 20 February 2018
US Patent 9,895,309, Selenosugars for skin tissue repair, Seleno Therapeutics Pty Ltd, 20 February 2018
US Patent 9,890,358, Latent neural stem cell population, University of Queensland, 13 February 2018
US Patent 9,890,203, Process for preparing apolipoprotein A-I (Apo A-I), CSL Ltd, 13 February 2018
US Patent 9,889,233, Method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair, Orthocell, 13 February 2018
US Patent 9,889,195, Immunogenic composition and uses thereof, University of Melbourne, 13 February 2018
US Patent 9,889,184, Anti-pathogen systems, Hexima, 13 February 2018
US Patent 9,888,679, Protection of progenitor cells and regulation of their differentiation, Proteobioactives Pty Ltd, 13 February 2018
US Patent 9,885,048, Method for reducing circulating leukocytes in a human subject, Antisense Therapeutics, 6 February 2018
US Patent 9,885,038, Gene silencing methods, Commonwealth Scientific and Industrial Research Organisation, 6 February 2018
US Patent 9,884,109, Compositions and methods, Macfarlane Burnet Institute for Medical Research and Public Health, 6 February 2018
US Patent 9,884,101, Treatment and prevention of malaria, Walter and Eliza Hall Institute for Medical Research, 6 February 2018
US Patent 9,884,034, Prevention of psychotic disorders and/or treatment of psychotic symptoms, Orygen Youth Health Research Centre, 6 February 2018
US Patent 9,878,043, Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells, EnGeneIC, 30 January 2018
US Patent 9,878,017, Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto, CSL Ltd, 30 January 2018
US Patent 9,877,981, NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation, Harvard University and University of New South Wales, 30 January 2018
US Patent 9,868,936, Cell culture method, Isopogen Pty Ltd, 16 January 2018
US Patent 9,868,763, Modulators of protease activated receptors, University of Queensland, 16 January 2018
US Patent 9,867,802, Method of treating Scedosporium spp. infection, Biodiem Ltd, 16 January 2018
US Patent 9,867,785, Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells, EnGeneIC, 16 January 2018
US Patent 9,861,714, Cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 9 January 2018
US Patent 9,861,679, Method of treating cancer, Walter and Eliza Hall Institute of Medical Research, 9 January 2018
US Patent 9,861,657, Treatment of bone marrow edema (oedema) with polysulfated polysaccharides, Paradigm Biopharma, 9 Jnauary 2018
US Patent 9,861,646, Dental compositions, Ozdent Pty Ltd, 9 January 2018
US Patent 9,856,326, Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies, CSL Ltd, 2 January 2018
US Patent 9,856,325, Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies, CSL Ltd, 2 January 2018

New Zealand applications

Here are the 3 patents relevant to New Zealand's Life Sciences sector that have been granted in 2018, for an issuance rate of 0.2 per week:

US Patent 9,943,558, Compositions and methods for treating multi-drug resistant malaria, Febris Bio-Tech Ltd, 17 April 2018
US Patent 9,877,991, Reaction platform and method for making pollen based materials in combination with beeswax and uses thereof, Decima Health, 30 January 2018
US Patent 9,867,823, Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders, Neuren Pharmaceuticals, 16 January 2018